Haisco Pharmaceutical (SHE:002653) received approval from China's National Medical Products Administration for the clinical trials of HSK46256 tablets, according to a Shenzhen bourse filing on Friday.
The drug was developed as a treatment for advanced solid tumors.
The Chinese drug company's shares rose 3% during the morning trade.